icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Thu 25 Jun 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Government websites use the protocol. HTTPS for encryption and security.

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Registered with the Digital Government Authority under number:
20250831619
Suggestions

A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation

A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation

icon 2022-06-27
عنوان الدراسة
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
داعم الدراسة
Novartis
دواء الدراسة
Ruxolitinib (INC424) (Jakavi)
رقم بروتوكول الدراسة
CINC424D2301
حالة الدراسة
Ongoing
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3